Fennec Pharmaceuticals' 15min Chart Sees KDJ Golden Cross and Bullish Marubozu

Fennec Pharmaceuticals' 15-minute chart recently experienced a KDJ Golden Cross and a Bullish Marubozu at 08/15/2025 09:45. This indicates a shift in momentum towards the upside, suggesting that the stock price has the potential to continue increasing. The dominance of buyers in the market indicates that bullish momentum is likely to persist.

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, recently reported its financial results for the second quarter ended June 30, 2025, and provided a business update. The company achieved total net revenues of $9.7 million, marking a 33% increase over the same quarter in 2024. This growth was driven by significant progress in both large community practices and academic centers, supported by a targeted sales strategy and enhanced patient support services for PEDMARK® [1].

The quarter also saw notable growth in new accounts, with a double-digit increase in both large community practices and academic centers. This growth was facilitated by an overhauled go-to-market approach and increased awareness of the importance of preventing cisplatin-induced ototoxicity (CIO). Additionally, Fennec Pharmaceuticals successfully launched PEDMARQSI® in the United Kingdom and Germany, with further European launches planned [1].

Key highlights from the quarter include the addition of PEDMARK® to the formulary of a large national oncology group for patients under 40, reflecting growing recognition of the need to protect younger patients from cisplatin-induced hearing loss. The NCODA PQI (Positive Quality Intervention) for PEDMARK® was also issued, providing clinical data and guidance for the use, administration, and timing of PEDMARK® to prevent platinum-induced ototoxicity in pediatric patients and the AYA population [1].

Fennec Pharmaceuticals also reported quarter-over-quarter growth in enrollment in its Fennec HEARS™ and Specialty Pharmacy Program, which has been delivering improved experiences through strengthened HCP and patient services, expanded payer reimbursement support, and streamlined access to home nursing resources. The company further strengthened its patent portfolio with the issuance of U.S. Patent 12,311,026, covering the use of a broad range of stabilizers or a mixture of stabilizers for the pharmaceutical composition of sodium thiosulfate to reduce ototoxicity in a pediatric patient receiving a platinum-based therapeutic [1].

The financial results for the second quarter 2025 ended June 30, 2025, showed net product sales of approximately $9.7 million compared to $7.3 million in the second quarter of 2024. Selling and marketing expenses were $4.4 million, while general and administrative (G&A) expenses were $7.0 million. Cash and cash equivalents were $18.7 million as of June 30, 2025, compared to $22.7 million as of March 31, 2025. The decrease in cash is primarily due to seasonally higher cash operating expenses in the first half of the Company’s calendar year [1].

Fennec Pharmaceuticals will ring the NASDAQ Stock Market closing bell in September and will present at the H.C. Wainwright 27th Annual Global Investment Conference. The company will also host one-on-one investor meetings at the conference and stand in solidarity with young people, families, and care teams impacted by cancer during Childhood Cancer Awareness Month in September [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/14/3133259/0/en/Fennec-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results-And-Provides-Business-Update.html